Idetrexed

• Description :

  Idetrexed (ONX 0801) is a thymidylate synthase (TS) inhibitor with a Ki of 1.2 nM. Idetrexed can be specifically transported into α-folate receptor (α-FR) -overexpressing tumors, such as ovarian cancer[1][2].

• Product Name Alternative :

  BGC 945; ONX-0801; CB 300945

• UNSPSC :

  12352005

• Target :

  Thymidylate Synthase

• Type :

  Reference compound

• Related Pathways :

  Apoptosis

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/idetrexed.html

• Solubility :

  10 mM in DMSO

• Smiles :

  C#CCN(C1=CC=C(C=C1)C(N[C@H](C(O)=O)CCC(N[C@@H](C(O)=O)CCC(O)=O)=O)=O)[C@@H]2C3=CC(C(N=C(N4)CO)=O)=C4C=C3CC2

• Molecular Formula :

  C32H33N5O10

• Molecular Weight :

  647.63

• References & Citations :

  [1]Gibbs DD, Theti DS, Wood N, Green M, Raynaud F, Valenti M, Forster MD, Mitchell F, Bavetsias V, Henderson E, Jackman AL. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res. 2005 Dec 15;65 (24) :11721-8.|[2]Tochowicz A, Dalziel S, Eidam O, O'Connell JD 3rd, Griner S, Finer-Moore JS, Stroud RM. Development and binding mode assessment of N-[4-[2-propyn-1-yl[ (6S) -4,6,7,8-tetrahydro-2- (hydroxymethyl) -4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targets tumor cells. J Med Chem. 2013 Jul 11;56 (13) :5446-55.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [501332-69-0]